PALLD sirna

PALLD siRNA (Human)

Cat. Num. AAA8221403

• Gene Names: PALLD; MYN; PNCA1; CGI151; SIH002; CGI-151
• Reactivity: Human
• Applications: RNA Interference (RNAi)
• Purity: > 97%
• Synonyms: PALLD; PALLD siRNA (Human); KIAA0992; Palladin; SIH002; Sarcoma antigen NY-SAR-77; PALLD sirna

• Host: Synthetic
• Reactivity: Human
• Specificity: PALLD siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
• Purity/Purification: > 97%
• Form/Format: Lyophilized powder
• Sequence Length: 1123

• Applicable Applications for PALLD sirna: RNA Interference (RNAi)
• Quality Control: Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
• Directions for Use: We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
• Components: We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human PALLD gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
• Preparation and Storage: Shipped at 4 degree C. Store at -20 degree C for one year.

Related Product Information for PALLD sirna

siRNA to inhibit PALLD expression using RNA interference

NCBI and Uniprot Product Information

• NCBI GI #: 260656030
• NCBI GeneID: 23022
• NCBI Accession #: NP_001159580.1
• NCBI GenBank Nucleotide #: NM_001166108.1
• UniProt Accession #: Q8WX93; Q7L3E0; Q7Z3W0; Q86WE8; Q8N1M2; Q9UGA0; Q9UQF5; Q9Y2J6; Q9Y3E9; B3KTG2; B5MD56; B7ZMM5
• Molecular Weight: 123,693 Da
• NCBI Official Full Name: palladin isoform 1
• NCBI Official Synonym Full Names: palladin, cytoskeletal associated protein
• NCBI Official Symbol: PALLD
• NCBI Official Synonym Symbols: MYN; PNCA1; CGI151; SIH002; CGI-151
• NCBI Protein Information: palladin
• UniProt Protein Name: Palladin
• Protein Family: Palladin
• UniProt Gene Name: PALLD
• UniProt Synonym Gene Names: KIAA0992
• UniProt Entry Name: PALLD_HUMAN

NCBI Description

This gene encodes a cytoskeletal protein that is required for organizing the actin cytoskeleton. The protein is a component of actin-containing microfilaments, and it is involved in the control of cell shape, adhesion, and contraction. Polymorphisms in this gene are associated with a susceptibility to pancreatic cancer type 1, and also with a risk for myocardial infarction. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Oct 2009]

Uniprot Description

palladin: Cytoskeletal protein required for organization of normal actin cytoskeleton. Roles in establishing cell morphology, motility, cell adhesion and cell-extracellular matrix interactions in a variety of cell types. May function as a scaffolding molecule with the potential to influence both actin polymerization and the assembly of existing actin filaments into higher-order arrays. Binds to proteins that bind to either monomeric or filamentous actin. Localizes at sites where active actin remodeling takes place, such as lamellipodia and membrane ruffles. Different isoforms may have functional differences. Involved in the control of morphological and cytoskeletal changes associated with dendritic cell maturation. Involved in targeting ACTN to specific subcellular foci. Genetic variations in PALLD are associated with susceptibility to pancreatic cancer type 1 (PNCA1). Expression is increased early in the development of pancreatic cancer: in normal-appearing whole tissue immediately adjacent to cancer, in the pre-cancer, and in both the familial and sporadic forms of the cancer. Genetic variations in PALLD may be associated with myocardial infarction. Belongs to the myotilin/palladin family. 9 isoforms of the human protein are produced by alternative splicing.

Protein type: Cytoskeletal; Motility/polarity/chemotaxis

Chromosomal Location of Human Ortholog: 4q32.3

Cellular Component: ruffle; focal adhesion; mitochondrion; lamellipodium; cytoplasm; plasma membrane; actin filament; nucleus; Z disc; actin cytoskeleton

Molecular Function: protein binding; actin binding; muscle alpha-actinin binding

Biological Process: cytoskeleton organization and biogenesis

Disease: Pancreatic Cancer, Susceptibility To, 1